November 4, 2009 - The Centers for Medicare and Medicaid Services (CMS) released the review copy of the 2010 Hospital Outpatient Prospective Payment System (HOPPS) final rule on Oct. 30, 2009.
The final rule provides the following, as summarized by the American College of Radiology (ACR):
November 4, 2009 – Canadian physicians can now treat patients suffering from life-threatening aneurysms in one of the body’s largest arteries with an endovascular graft delivered during a minimally invasive procedure without blocking a critical artery.
November 3, 2009 – Vascular Solutions Inc. recently launched the Guardian II Hemostasis Valve. Unlike conventional rotating hemostasis valves, the Guardian II has an ergonomic click-open and click-close design to provide protection during interventions and separation of multiple guide wires and other devices used in the catheterization procedure.
November 3, 2009 — CardiacAssist Inc. said yesterday the Cardiovascular Institute of Stanford University Hospital and Clinics in Palo Alto, Calif., is one of the newest cardiac centers to begin using TandemHeart extracorporeal circulatory support system.
November 3, 3009 — On Monday, Andrea Natale, M.D., FACC, FHRS, an electrophysiologist and executive medical director of the Texas Cardiac Arrhythmia Institute at St. David's Medical Center, became the first physician in the United States to perform an ablation procedure to treat a patient with a cardiac arrhythmia using the newly FDA-cleared CARTO 3 Navigation System.
Carestream Health’s SuperPACS architecture streamlines workflow by equipping radiologists in any on-site or remote location to read from a global worklist that provides a unified set of imaging studies created from multiple vendors’ PACS located throughout the enterprise.
CardIQ Xpress Elite computed tomography angiography analysis software allows more speed and information so users can make an accurate, confident diagnosis. With the new AutoLaunch capability, images are ready to read and review in real time, improving workflow by up to 40 percent.
November 3, 2009 – Abbott yesterday said both the XIENCE PRIME Everolimus-Eluting Coronary Stent System and the XIENCE V Everolimus-Eluting Coronary Stent System have received additional new CE markings covering the treatment of patients with diabetes.
